Full View

Rivaroxaban (BAY 59‐7939)–an oral, direct Factor Xa inhibitor–has no clinically relevant interaction with naproxen

D Kubitza, M Becka, W Mueck… - British journal of clinical …, 2007 - Wiley Online Library
What is already known about this subject• Rivaroxaban is a novel anticoagulant with
predictable, dose‐proportional pharmacokinetics and pharmacodynamics in healthy …
被引用次数：228 相关文章

[引用][C] Rivaroxaban (BAY 59-7939)? an oral, direct Factor Xa inhibitor? has no clinically relevant interaction with naproxen

D Kubitza, M Becka, W Mueck… - British Journal of Clinical …, 2007 - cir.nii.ac.jp
Rivaroxaban (BAY 59-7939) ? an oral, direct Factor Xa inhibitor ? has no clinically relevant
interaction with naproxen | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Rivaroxaban (BAY 59-7939)–an oral, direct Factor Xa inhibitor–has no clinically relevant interaction with naproxen.

D Kubitza, M Becka, W Mueck… - British Journal of …, 2007 - search.ebscohost.com
What is already known about this subject• Rivaroxaban is a novel anticoagulant with
predictable, dose-proportional pharmacokinetics and pharmacodynamics in healthy …

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

D Kubitza, M Becka, W Mueck… - British Journal of Clinical …, 2006 - europepmc.org
Aims Rivaroxaban (BAY 59-7939) is in advanced clinical development for the prevention
and treatment of thromboembolic disorders. Frequent co-medications in the patient …

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

D Kubitza, M Becka, W Mueck… - British journal of …, 2007 - pubmed.ncbi.nlm.nih.gov
Aims Rivaroxaban (BAY 59-7939) is in advanced clinical development for the prevention
and treatment of thromboembolic disorders. Frequent co-medications in the patient …
[HTML] nih.gov

[HTML][HTML] Rivaroxaban (BAY 59-7939)–an oral, direct Factor Xa inhibitor–has no clinically relevant interaction with naproxen

D Kubitza, M Becka, W Mueck… - British Journal of Clinical …, 2007 - ncbi.nlm.nih.gov
Aims Rivaroxaban (BAY 59-7939) is in advanced clinical development for the prevention
and treatment of thromboembolic disorders. Frequent co-medications in the patient …

[引用][C] Rivaroxaban (BAY 59-7939)-: an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen

D KUBITZA, M BECKA, W MUECK… - British journal of …, 2007 - pascal-francis.inist.fr
Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant
interaction with naproxen CNRS Inist Pascal-Francis CNRS Pascal and Francis …

[引用][C] Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen

D KUBITZA - Br J Clin Pharmacol., 2007 - cir.nii.ac.jp

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

D Kubitza, M Becka, W Mueck… - British Journal of Clinical …, 2006 - europepmc.org
Aims Rivaroxaban (BAY 59-7939) is in advanced clinical development for the prevention
and treatment of thromboembolic disorders. Frequent co-medications in the patient …

[引用][C] Rivaroxaban (BAY 59-7939)-: an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen

D KUBITZA, M BECKA, W MUECK… - British journal of clinical …, 2007 - Blackwell